Tata Consultancy Services (TCS), a leading IT services, consulting and business solutions organisation, has been designated as a leader in Life Science Drug Safety Services (DSS) by the global market intelligence firm IDC.

Among the attributes that earned TCS its leadership position in the “IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment” (Document No. HI239221) are the company’s significant industry expertise, strong drug safety IT and KPO delivery capabilities and investment in drug safety specific IP assets.

“TCS large life science customer base, broad industry-centric services portfolio, competitive pricing, and strong commitment to growth ensure that the company will continue to be a leading service provider to the industry over both the near and long term,” said Dr Alan S Louie, research director, Clinical Development Strategy and Technology, IDC Health Insights.

“For TCS and our Life Sciences customers, patient safety is the absolute priority and we are honoured to be listed as a Leader by IDC Health Insights in the Drug Safety market,” said Debashis Ghosh, president, Life Sciences, Manufacturing and Energy at TCS.

“This recognition is a testament to our commitment to our customers, of constantly innovating and delivering superior drug safety services, and helping companies in ensuring enhanced care for their patients,” he added.

“Our differentiated strategy to provide core business services by investing in deep domain expertise and regulatory knowledge has enabled us to achieve this. TCS market leading capabilities in the drug safety space, including adverse event tracking and aggregate reporting, help the pharmaceutical industry meet their compliance requirements more effectively,” said Abid Ali Neemuchwala, global head, TCS BPO Services.